医师调查：製药公司排名堪称一流，但并非尽善尽美

医师并非独自做出治疗决策。他们依赖与同事的讨论、最新的临床研究以及包括製药公司在内的可靠资讯来源。医学事务团队致力于透过提供合适的内容来满足他们的需求。

了解医生从哪里获取资讯、他们如何评估所接收资讯的品质以及他们获取资讯的习惯，是医学事务专业人员了解医生真实需求的关键。

为了撰写本报告，我们调查了法国、德国、义大利、西班牙、英国和美国的 426 位医生，以了解他们对製药公司如何满足其医疗资讯需求和偏好的看法。医生从事五个专业：心臟科（n=135）、内分泌学（n=53）、神经病学（n=90）、肿瘤学（n=98）和风湿病学（n=50）。

关键问题解答

• 1. 整体而言，您对目前取得药物治疗和疾病资讯的途径满意吗？
• 2. 与其他来源相比，您多久会将製药公司作为您获取药物和疾病资讯的首选？
• 3. 您认为製药公司提供的药物和疾病资讯的可信度如何？
• 4. 製药公司提供的药物和疾病资讯与您的需求和兴趣有多相关？
• 5. 您认为您从製药公司获得的药物和疾病资讯的及时性如何？

Physicians don't make treatment decisions on their own. They rely on discussions with colleagues, the latest clinical research and trusted sources - including pharma - to inform them. Medical affairs teams seek to meet doctors' needs by delivering tailored, relevant content.

Determining where physicians go for answers, how they gauge the quality of the information they receive and their habits when it comes to consuming it is key to helping medical affairs professionals get to the heart of what doctors want and need.

To help shed light on this, FirstWord polled 426 physicians from France, Germany, Italy, Spain, the UK, and the US to gather their views on how well pharma is meeting their medical information needs and preferences. The doctors work across five specialties: cardiology (n = 135), endocrinology (n = 53), neurology (n = 90), oncology (n = 98), and rheumatology (n = 50).

Key Questions Answered:

• 1. How satisfied are you overall, with your current access to information relating to drug treatments and disease?
• 2. Please indicate how often pharmaceutical companies are your first choice for accessing drug and disease information versus other sources.
• 3. How reliable do you consider the drug and disease information that comes from pharmaceutical companies?
• 4. How relevant to your needs/interests is the drug and disease information that comes from pharmaceutical companies?
• 5. How timely is the drug and disease information that comes from pharmaceutical companies?

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.